The role of EREG/EGFR pathway in tumor progression
WL Cheng, PH Feng, KY Lee, KY Chen… - International journal of …, 2021 - mdpi.com
Aberrant activation of the epidermal growth factor receptor (EGFR/ERBB1) by erythroblastic
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …
Epiregulin: roles in normal physiology and cancer
DJ Riese II, RL Cullum - Seminars in cell & developmental biology, 2014 - Elsevier
Epiregulin is a 46-amino acid protein that belongs to the epidermal growth factor (EGF)
family of peptide hormones. Epiregulin binds to the EGF receptor (EGFR/ErbB1) and ErbB4 …
family of peptide hormones. Epiregulin binds to the EGF receptor (EGFR/ErbB1) and ErbB4 …
Single and dual targeting of mutant EGFR with an allosteric inhibitor
Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-
competitive kinase inhibitors due to their distinct sites of target binding. In this study, we …
competitive kinase inhibitors due to their distinct sites of target binding. In this study, we …
Pathogenesis of lung cancer signalling pathways: roadmap for therapies
E Brambilla, A Gazdar - European Respiratory Journal, 2009 - Eur Respiratory Soc
Lung cancer is the major cancer killer worldwide, and 5-yr survival is extremely poor (≤
15%), accentuating the need for more effective therapeutic strategies. Significant advances …
15%), accentuating the need for more effective therapeutic strategies. Significant advances …
The ERBB network facilitates KRAS-driven lung tumorigenesis
B Kruspig, T Monteverde, S Neidler, A Hock… - Science translational …, 2018 - science.org
KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the
lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung …
lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung …
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines
Background Deregulation of EGFR signaling is common in non-small cell lung cancers
(NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are …
(NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are …
[HTML][HTML] Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine
M Rivera, I Fichtner, A Wulf-Goldenberg, C Sers, J Merk… - Neoplasia, 2021 - Elsevier
Patient-derived xenograft (PDX) tumor models represent a valuable platform for identifying
new biomarkers and novel targets, to evaluate therapy response and resistance …
new biomarkers and novel targets, to evaluate therapy response and resistance …
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors
M Sun, C Behrens, L Feng, N Ozburn, X Tang, G Yin… - Clinical cancer …, 2009 - AACR
Purpose: To compare the characteristics of deregulation of HER receptors and their ligands
between primary tumor and corresponding brain metastases of non–small cell lung …
between primary tumor and corresponding brain metastases of non–small cell lung …
Tumor-associated monocytes promote mesenchymal transformation through EGFR signaling in glioma
The role of brain immune compartments in glioma evolution remains elusive. We profile
immune cells in glioma microenvironment and the matched peripheral blood from 11 …
immune cells in glioma microenvironment and the matched peripheral blood from 11 …
Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer
S Ma, L Zhang, Y Ren, W Dai, T Chen, L Luo, J Zeng… - Oncogene, 2021 - nature.com
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective against
non-small cell lung cancer (NSCLC) with EGFR-activating mutations. The mechanisms …
non-small cell lung cancer (NSCLC) with EGFR-activating mutations. The mechanisms …